Population- based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. American Heart Journal. 2006; 152(5):941-948 2. Ademi Z, Pasupathi K, Krum H, Liew D. Cost effectiveness of eplerenone in patients with chronic heart failure. American Journal of Cardiovascular Drugs. 2014; 14(3):209-16 3. Ademi Z, Pasupathi K, Liew D. Cost-effectiveness of eplerenone compared to usual care in patients with chronic heart failure and NYHA class ii symptoms, an Australian perspective. 4. Adlbrecht C, Huelsmann M, Berger R, Moertl D, Strunk G, Oesterle A et al. Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home- based nurse care. European Journal of Clinical Investigation. 2011; 41(3):315-22 5. Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M et al. Spironolactone improves lung diffusion in chronic heart failure. European Heart Journal. 2005; 26(2):159-164 6. Agvall B, Alehagen U, Dahlstrom U. The benefits of using a heart failure management programme in Swedish primary healthcare. European Journal of Heart Failure. 2013; 7. Al-Sutari MM, Ahmad MM. Effect of educational program on self-care behaviors and health outcome among patients with heart failure: an experimental study. International Journal of Evidence Based Healthcare. 2017; 15(4):178-185 8. Aldred H, Gott M, Gariballa S. Advanced heart failure: impact on older patients and informal carers. Journal of Advanced Nursing. 2005; 49(2):116-24 9. All Party Parliamentary Group on Heart Disease. Focus on heart failure: 10 recommendations to improve care and transform lives. London. British Heart Foundation, 2016. 10. Allen LA, Matlock DD, Shetterly SM, Xu S, Levy WC, Portalupi LB et al. Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. JAMA 11. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M et al. 